



## ASX ANNOUNCEMENT

2 April 2007

### HeartWare Opens Fourth Implant Centre

HeartWare is pleased to announce that it has successfully commenced implanting at the Harefield Hospital in the United Kingdom. Harefield Hospital is HeartWare's third European centre and this brings the total number of implant centres to four following a series of implants at Vienna General Hospital, Royal Perth Hospital and Hannover Medical Centre.

On 28 March 2007, the cardiothoracic team at Harefield Hospital in the United Kingdom conducted their first implant of HeartWare's HVAD™ Left Ventricular Assist Device. The device was implanted in a 44 year old male patient suffering advanced heart failure. The procedure was completed quickly and without incident and the patient continues to recover well from the surgery.

In a statement, Mr. Asghar Khaghani, Consultant Cardiac and Transplant Surgeon, Royal Brompton & Harefield NHS Trust, Harefield Hospital commented:

*"We are very impressed with the HeartWare device. Our first implant of the pump went extremely well. The pump's small size and integrated inflow cannula allow implantation entirely above the diaphragm. This enables an easy and relatively quick surgical procedure which we expect will translate into improved outcomes for our patients. Our first patient continues to make an excellent recovery and we are looking forward to conducting our second implant of the pump."*

#### Clinical Trial Update

To date, eleven patients have been implanted with the HVAD™, including five at Vienna General Hospital, three at Royal Perth Hospital, two at Hannover Medical Centre and one at Harefield Hospital. On a cumulative basis, these patients have been supported for a total of over 1,400 days. The average implant duration across the patient population exceeds 130 days.

During the last week, HeartWare's second and third patient both received a heart transplant. Our second patient had been supported by the HVAD™ for 347 days while the third patient had been supported for 157 days. The pump performed well in both patients over the entire period, during which the patients were awaiting the availability of a suitable donor heart. Both transplants were successful and the patients are recovering well.

The primary endpoint for the HVAD™ clinical trial is patient survival, either to 180 days or to transplantation. Of the 11 patients enrolled in the trial, three have successfully met the trial endpoint. These include the two patients referred to above, together with HeartWare's first patient who has been supported by his pump for 376 days.



## About HeartWare

HeartWare is developing a family of proprietary circulatory assist devices to treat patients with heart failure. HeartWare's lead device, the HVAD™, is currently progressing through an international clinical trial. With a volume of 45cc, the HVAD™ is the smallest "3rd generation" pump and the only full output device implantable routinely within the thoracic cavity.

HeartWare's miniaturization platform enables the development of smaller devices, potentially implantable by minimally invasive surgical techniques. Pre-clinical studies are underway for HeartWare's MVAD™, a pump one third the size of the HVAD™. HeartWare's IV-VAD™, a pump one tenth the size of the HVAD™, is at early prototype stage.

For further information:

[www.heartware.com.au](http://www.heartware.com.au)  
Howard Leibman  
Director Corporate Development  
HeartWare Limited  
+61 2 8215 7604 / 0402 440644

Media enquiries:

Stuart Barton  
Gavin Anderson & Company  
+61 2 9552 4499 / 0404 054 857